Groesbeck Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Groesbeck Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-16,874	Closed	-$3.22M	–	93
2015 Q4	$3.22M	Sell	16,874 -29	-0.2%	-$5.07K	2.05%	15
2015 Q3	$2.64M	Hold	16,903	–	–	1.67%	22
2015 Q2	$3.06M	Hold	16,903	–	–	1.46%	24
2015 Q1	$2.93M	Buy	16,903 +289	+2%	+$52.3K	1.42%	25
2014 Q4	$3.07M	Buy	16,614 +10,000	+151%	+$1.85M	1.51%	24
2014 Q3	$1.1M	Hold	6,614	–	–	0.52%	57
2014 Q2	$1.03M	Buy	6,614 +5,300	+403%	+$837K	0.45%	59
2014 Q1	$200K	Buy	+1,314	New	+$209K	0.09%	85

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Groesbeck Investment Management's ALXN Position: Q1 2016 in Review

Groesbeck Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 16,874 shares — an estimated $3.22M sold.

Groesbeck Investment Management first reported a position in ALXN in Q1 2014 and held it in 8 quarters. The position peaked at $3.22M in Q4 2015. 519 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

Groesbeck Investment Management reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Groesbeck Investment Management sold 16,874 Alexion Pharmaceuticals shares in Q1 2016, an estimated $3.22M.
Groesbeck Investment Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Groesbeck Investment Management's Alexion Pharmaceuticals position peaked at $3.22M in Q4 2015.
519 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Groesbeck Investment Management's 13F filing for Q1 2016, filed 13 May 2016.